Information Provided By:
Fly News Breaks for September 13, 2017
Sep 13, 2017 | 07:43 EDT
After Sage's Brexanolone drug missed the primary and secondary endpoints of its Phase 3 trial involving Super-Refractory Status Epilepticus, or SRSE, patients, Needham analyst Danielle Brill says the results do not impact her view of the drug's efficacy in post-partum depression, or PPD,. She says that PPD is much easier to treat than SRSE, while the drug;s mechanism of action is different in PPD versus SRSE. The analyst notes that the drug demonstrated that it lowered PPD by statistically significant amounts in a previous trial. She cut her price target on the stock to $86 from $95 but keeps a Buy rating on the shares.
News For SAGE From the Last 2 Days
There are no results for your query SAGE
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.